FDA approves Talzenna for metastatic, castration-resistant prostate cancer
The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Jun 27, 2023
0
2